700 Journals and 15,000,000 Readers
Each Journal is getting 25,000+ Readers
Journal of Immunooncology is one of the most promising and rapidly developing areas of cancer research. The journal focuses on the development of new therapies which improve human body’s immune response against cancer.
Journal of Immunooncology is focused on publishing articles on various areas of immunotherapy like cancer immunotherapy, tumor immunology, immune system, nucleic acid research, immune suppression, immunosurveillance, tumor immunity, cellular immunotherapy, cancer radioimmunotherapy, cancer immunology, cancer immunoediting, immunotherapeutics, immunogenicity and recent research in these areas. The Journal provides an open access platform to publish latest advancements in all aspects related to immune-oncology.
This Journal provides a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on any array of Immuno-oncology. The Journal of Immunooncology is a Peer Reviewed Open Access Journal supported by universally prominent Editorial Board members. Abstracts and full texts of all articles published by Journal of Immunooncology are freely accessible to everyone immediately after publication.
The journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal of Immunooncology or outside experts; approval of at least two independent reviewers followed by the editor is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.
Cancer Immunotherapies is the treatment that uses certain parts of the immune system to fight against diseases like cancer. It is also known as biotherapy or biologic therapy. Antibody therapies are the most successful immunotherapy as it treats wide range of cancers. Immunotherapies fall into three main groups: cellular, antibody and cytokine.
Related Journals of Cancer Immunotherapies
Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. It is not actually clear how immunotherapy treats cancer.
Related Journals of Immunotherapies
Tumour Immunology is also known as cancer immunology. It is a branch of immunology that studies interactions between the immune systems and the cancer cells. It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease.
Related Journals of Tumour Immunology
Necrosis is the death of most or all of the cells in an organ or tissue due to disease, injury, or failure of the blood supply. Necrosis is caused by external factors to the cell or tissue, such as infection, toxins, or trauma that result in the unregulated digestion of cell components.
Related Journals of Necrosis
Nucleic Acid Research is the research on nucleic acids such as DNA, RNA and related work. It deals with the physical, chemical and biological aspects of the nucleic acids.
Related Journals of Nuclie Acid Research
Immunosuppression involves an act that decreases the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
Related Journals of Immunosuppression
Immunosurveillance is a term used to describe the processes by which cells of the immune system look for and recognise foreign pathogens, such as bacteria and viruses, or pre-cancerous and cancerous cells in the body. Cancer immunosurveillance appears to be an important host protection process that decreases cancer rates through inhibition of carcinogenesis and maintaining of regular cellular homeostasis.
Related Journals of Immunosurveillance
The immune response to foreign antigens consists of humoral (eg, antibodies) and cellular mechanisms. Most of the humoral responses cannot prevent tumor growth. However, effector cells, such as T cells, macrophages, and natural killer cells, have relatively effective tumoricidal abilities.
Related Journals of Tumour Immunity
Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. It is not entirely clear how immunotherapy treats cancer.
Related Journals of Immunotherapy or biologic therapy
Immunobiology, Immunotherapy: Open Access, Immunome Research, Cancer Immunology and Immunotherapy, Journal of Immunotherapy, Immunotherapy, International Journal of Immunotherapy
Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. A tumor formed by metastatic cancer cells is called a metastatic tumor or a metastasis. The process by which cancer cells spread to other parts of the body is also called metastasis.
The immune system is a system of many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue.
Related Journals of Systems of Immune
Chemotherapy is a type of cancer treatment that uses chemical substances, especially one or more anti-cancer drugs that are given as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent, or it may aim to prolong life or to reduce symptoms.
Related Journals of Chemotherapies
Chemotherapy: Open Access, Antimicrobial Agents and Chemotherapy, Cancer Chemotherapy and Pharmacology, Chemotherapy, Journal of Chemotherapy, Japanese Journal of Chemotherapy, Antibiotics and chemotherapy
Radioimmunotherapy (RIT) uses an antibody labelled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues.
Related Journals of Cancer Radioimmunotherapy
Cellular Immunotherapy has the potential to be a highly targeted alternative, with low toxicity to normal tissues but a high capacity to eradicate tumor. It includes the approaches that generate cellular therapies using active immunization with cells, proteins, peptides, or nucleic acids, as well as efforts that use adoptive transfer of effector cells that directly target antigens on malignant cells.
Related Journals of Cellular Immunotherapy
Cancer Immunology and Immunotherapy, Journal of Immunotherapy, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Immunotherapy, International Journal of Immunotherapy, Serodiagnosis and Immunotherapy in Infectious Disease
Cancer Immunology is also known as tumour immunology. It is a branch of immunology that studies interactions between the immune systems and the cancer cells. It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease.
Related Journals of Cancer Immunology
The involvement of the immune system in the host response to tumors is complex and involves lymphocytes and lymphocyte-derived mediators, as well as inflammatory cells and various other agents such as complement. These activities are not confined to cytodestructive processes; recent studies demonstrate that the migration characteristics of tumor cells may be modified by immunologically derived substances.
Related Journals of Tumour Immunity
Immunoediting is characterized by changes in the immunogenicity of tumours due to the anti-tumour response of the immune system, resulting in the emergence of immune-resistant variants. It consists of 3 phases- elimination, equilibrium and escape.
Related Journals of Cancer Immunoediting
Journal of the National Cancer Institute. Monographs, Cancer Investigation, Cancer Genetics and Cytogenetics, European Journal of Cancer Prevention, Cancer Journal
Immunotherapeutic agents use or modify immune mechanisms. Use of these agents is rapidly evolving; new classes, new agents, and new uses of current agents are certain to be developed. Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response".
Related Journals of Immunotherapeutic agents
Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. In other words, immunogenicity is the ability to induce a humoral and/or cell mediated immune response.
Related Journals of Immunogene response
The cancerous cells appear to be present and proliferating in an abnormal huge quantity within the line of epithelial cells of urinary bladder is termed as Bladder CIS (Carcinoma in situ). The term CIS is also known as in situ neoplasm where the cancerous cells accumulate as a neoplasm on the outer dermis but fails to penetrate the epithelial wall and doesn’t spread into the inner one.
The most common type of urinary cancer also known as the creeping tumor arises from the transitional dermis and spreads along the urothelial cellular lining of the organs of urinary system which hails damage to urinary system, kidney, urinary bladder, and accessory organs. The cancerous cells are formed in the renal pelvis and ureter.
Related Journals of Transitional Cell Carcinoma (TCC)
Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, Clinical Genitourinary Cancer, Breast Cancer Research, Prostate Cancer and Prostatic Diseases, Clinical Colorectal Cancer, Gastric and Breast Cancer